Technology ID
TAB-2729
Immunogenic Hepatitis E Virus Polypeptides for Vaccine and Diagnostics Development
E-Numbers
E-152-2013-0
Lead Inventor
Fields, Howard (CDC)
Co-Inventors
Khudyakov, Yury (CDC)
Meng, Jihong (CDC)
Applications
Vaccines
Therapeutics
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Immunology
Endocrinology
Dental
Cardiology
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
Research Products
Antibodies
Lead IC
CDC
ICs
CDC
This technology comprises specific hepatitis E virus (HEV) antigenic polypeptides. HEV causes epidemic and sporadic cases of hepatitis outbreaks with a mortality rate as high as 20% for pregnant women. In order to address this problem, CDC scientists carried out thorough HEV antigen screenings and subsequently developed recombinant proteins that efficiently model major HEV neutralization epitope(s). These recombinant proteins may be considered as candidates for the development of an HEV subunit vaccine, as well as for the development of highly sensitive and specific diagnostic tests.
Commercial Applications
- Development of a peptide subunit-based vaccine for hepatitis E virus (HEV)
- Development of HEV sero-diagnostic tools and reagents
- Blood transfusion screening
- Pregnancy screening safety precautions
- Hepatitis monitoring programs
- Basic research into hepatitis pathogenicity and immune response
Competitive Advantages
- Generated antibodies were cross-reactive with a number of geographically distinct HEV strains
- Useful for development of highly sensitive and specific diagnostic tests
- Could be useful for improving efficacy and HEV-strain immunity provided by current vaccine(s)
Licensing Contact: